Pfizer Announces Acquisition of Metsera in $4.9 Billion Deal to Expand Obesity Treatment Portfolio
Pfizer Inc. has announced its acquisition of Metsera for $4.9 billion, paying $47.50 per share in cash. The deal includes a contingent value right that could yield additional payments of up to $22.50 per share based on clinical and regulatory milestones. The transaction is expected to close in Q4 2025, subject to regulatory approvals. Citi is Pfizer's financial advisor, while Metsera's advisors include Goldman Sachs and Guggenheim Securities.
Pfizer Inc. has announced its agreement to acquire all outstanding shares of Metsera common stock for $47.50 per share in cash, valuing the transaction at approximately $4.9 billion. The agreement includes a contingent value right (CVR) that could provide Metsera shareholders with additional cash payments of up to $22.50 per share tied to the achievement of certain clinical and regulatory milestones. The transaction is expected to close in the fourth quarter of 2025, pending customary closing conditions and regulatory approvals. Citi is serving as Pfizer’s financial advisor, with Wachtell, Lipton, Rosen & Katz as legal advisor. Metsera’s financial advisors include Goldman Sachs & Co. LLC, Guggenheim Securities, LLC, BofA Securities, Inc., and Allen & Company LLC, with Paul, Weiss, Rifkind, Wharton & Garrison LLP as legal advisor.
